VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Nature medicine, 2017•nature.com
Abstract To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not
been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To
identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we
evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical
trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets
of macrophages in treated tumors. Our data suggest that VISTA represents another …
been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To
identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we
evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical
trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets
of macrophages in treated tumors. Our data suggest that VISTA represents another …
Abstract
To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.
nature.com